A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers

K. Behbakht, L. S. Massad, E. L. Yordan, S. H. Lincoln, J. A H Eriksson, L. Winkelman, Koenraad De Geest, C. Kirschner, G. D. Wilbanks

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Persistent or recurrent squamous malignancies of the female genital tract are usually incurable by conventional therapy, and results of single agent chemotherapy have been disappointing. We undertook this study to confirm a previously reported response rate of 69%, using a regimen of bleomycin 30U, ifosfamide 5g/m2 with mesna 6g/m2, and cisplatin 50 mg/m2 (BIP) for recurrent cervical cancer. This regimen was used to treat persistent or recurrent squamous cancers in women with cervical cancer (n = 11), vaginal cancer (n = 1) and vulvar cancer (n = 1). Results were reviewed retrospectively and toxicities graded according to the criteria of the Gynecologic Oncology Group. No complete responses were seen. One patient had a partial response (10%, 95% confidence interval 0-28%). Five patients (50%), exhibiting stable disease during therapy with BIP, progressed after cessation of therapy. Of 9 women with symptoms after one cycle. Significant toxicities included neutropenic fever (3 grade 3, 3 grade 4), emesis (1 grade 3), confusion (2 grade 4), vaginal bleeding (2 grade 3), and renal failure (1 grade 3). Eight patients were transfused with a total of 28 units of red cells. After 23 months of follow-up, all patients were dead of disease. Mean survival was 10 months. Toxicity associated with this regimen can be significant, and results appear no better than those reported with single agent therapy.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalEuropean Journal of Gynaecological Oncology
Volume17
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Ifosfamide
Bleomycin
Cisplatin
Uterine Cervical Neoplasms
Neoplasms
Vaginal Neoplasms
Mesna
Vulvar Neoplasms
Uterine Hemorrhage
Therapeutics
Vomiting
Renal Insufficiency
Fever
Confidence Intervals
Drug Therapy
Survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Behbakht, K., Massad, L. S., Yordan, E. L., Lincoln, S. H., Eriksson, J. A. H., Winkelman, L., ... Wilbanks, G. D. (1996). A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers. European Journal of Gynaecological Oncology, 17(1), 7-12.

A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers. / Behbakht, K.; Massad, L. S.; Yordan, E. L.; Lincoln, S. H.; Eriksson, J. A H; Winkelman, L.; De Geest, Koenraad; Kirschner, C.; Wilbanks, G. D.

In: European Journal of Gynaecological Oncology, Vol. 17, No. 1, 1996, p. 7-12.

Research output: Contribution to journalArticle

Behbakht, K, Massad, LS, Yordan, EL, Lincoln, SH, Eriksson, JAH, Winkelman, L, De Geest, K, Kirschner, C & Wilbanks, GD 1996, 'A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers', European Journal of Gynaecological Oncology, vol. 17, no. 1, pp. 7-12.
Behbakht, K. ; Massad, L. S. ; Yordan, E. L. ; Lincoln, S. H. ; Eriksson, J. A H ; Winkelman, L. ; De Geest, Koenraad ; Kirschner, C. ; Wilbanks, G. D. / A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers. In: European Journal of Gynaecological Oncology. 1996 ; Vol. 17, No. 1. pp. 7-12.
@article{9344e32a01a34bab9e77dc1ea1c09c82,
title = "A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers",
abstract = "Persistent or recurrent squamous malignancies of the female genital tract are usually incurable by conventional therapy, and results of single agent chemotherapy have been disappointing. We undertook this study to confirm a previously reported response rate of 69{\%}, using a regimen of bleomycin 30U, ifosfamide 5g/m2 with mesna 6g/m2, and cisplatin 50 mg/m2 (BIP) for recurrent cervical cancer. This regimen was used to treat persistent or recurrent squamous cancers in women with cervical cancer (n = 11), vaginal cancer (n = 1) and vulvar cancer (n = 1). Results were reviewed retrospectively and toxicities graded according to the criteria of the Gynecologic Oncology Group. No complete responses were seen. One patient had a partial response (10{\%}, 95{\%} confidence interval 0-28{\%}). Five patients (50{\%}), exhibiting stable disease during therapy with BIP, progressed after cessation of therapy. Of 9 women with symptoms after one cycle. Significant toxicities included neutropenic fever (3 grade 3, 3 grade 4), emesis (1 grade 3), confusion (2 grade 4), vaginal bleeding (2 grade 3), and renal failure (1 grade 3). Eight patients were transfused with a total of 28 units of red cells. After 23 months of follow-up, all patients were dead of disease. Mean survival was 10 months. Toxicity associated with this regimen can be significant, and results appear no better than those reported with single agent therapy.",
author = "K. Behbakht and Massad, {L. S.} and Yordan, {E. L.} and Lincoln, {S. H.} and Eriksson, {J. A H} and L. Winkelman and {De Geest}, Koenraad and C. Kirschner and Wilbanks, {G. D.}",
year = "1996",
language = "English (US)",
volume = "17",
pages = "7--12",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "1",

}

TY - JOUR

T1 - A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers

AU - Behbakht, K.

AU - Massad, L. S.

AU - Yordan, E. L.

AU - Lincoln, S. H.

AU - Eriksson, J. A H

AU - Winkelman, L.

AU - De Geest, Koenraad

AU - Kirschner, C.

AU - Wilbanks, G. D.

PY - 1996

Y1 - 1996

N2 - Persistent or recurrent squamous malignancies of the female genital tract are usually incurable by conventional therapy, and results of single agent chemotherapy have been disappointing. We undertook this study to confirm a previously reported response rate of 69%, using a regimen of bleomycin 30U, ifosfamide 5g/m2 with mesna 6g/m2, and cisplatin 50 mg/m2 (BIP) for recurrent cervical cancer. This regimen was used to treat persistent or recurrent squamous cancers in women with cervical cancer (n = 11), vaginal cancer (n = 1) and vulvar cancer (n = 1). Results were reviewed retrospectively and toxicities graded according to the criteria of the Gynecologic Oncology Group. No complete responses were seen. One patient had a partial response (10%, 95% confidence interval 0-28%). Five patients (50%), exhibiting stable disease during therapy with BIP, progressed after cessation of therapy. Of 9 women with symptoms after one cycle. Significant toxicities included neutropenic fever (3 grade 3, 3 grade 4), emesis (1 grade 3), confusion (2 grade 4), vaginal bleeding (2 grade 3), and renal failure (1 grade 3). Eight patients were transfused with a total of 28 units of red cells. After 23 months of follow-up, all patients were dead of disease. Mean survival was 10 months. Toxicity associated with this regimen can be significant, and results appear no better than those reported with single agent therapy.

AB - Persistent or recurrent squamous malignancies of the female genital tract are usually incurable by conventional therapy, and results of single agent chemotherapy have been disappointing. We undertook this study to confirm a previously reported response rate of 69%, using a regimen of bleomycin 30U, ifosfamide 5g/m2 with mesna 6g/m2, and cisplatin 50 mg/m2 (BIP) for recurrent cervical cancer. This regimen was used to treat persistent or recurrent squamous cancers in women with cervical cancer (n = 11), vaginal cancer (n = 1) and vulvar cancer (n = 1). Results were reviewed retrospectively and toxicities graded according to the criteria of the Gynecologic Oncology Group. No complete responses were seen. One patient had a partial response (10%, 95% confidence interval 0-28%). Five patients (50%), exhibiting stable disease during therapy with BIP, progressed after cessation of therapy. Of 9 women with symptoms after one cycle. Significant toxicities included neutropenic fever (3 grade 3, 3 grade 4), emesis (1 grade 3), confusion (2 grade 4), vaginal bleeding (2 grade 3), and renal failure (1 grade 3). Eight patients were transfused with a total of 28 units of red cells. After 23 months of follow-up, all patients were dead of disease. Mean survival was 10 months. Toxicity associated with this regimen can be significant, and results appear no better than those reported with single agent therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030066295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030066295&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 7

EP - 12

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 1

ER -